microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity

[11] Selvaraj A(2008)Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer The Journal of clinical investigation 118 3065-3074

[12] Liu Y(2005)The coordinate regulation of the p53 and mTOR pathways in cells Proceedings of the National Academy of Sciences of the United States of America 102 8204-8209

[13] Kozma SC(2005)Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23 7721-7735

[14] Thomas G(2003)Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Molecular endocrinology 17 575-588

[15] Sonenberg N(2011)The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells Molecular endocrinology 25 516-528

[16] Gulhati P(2005)Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clinical cancer research : an official journal of the American Association for Cancer Research 11 5319-5328

[17] Bowen KA(2007)Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells The Journal of surgical research 138 37-44

[18] Liu J(2013)The UCSC Cancer Genomics Browser: update 2013 Nucleic acids research 41 D949-954

[19] Stevens PD(2011)The UCSC Cancer Genomics Browser: update 2011 Nucleic acids research 39 D951-959

[20] Rychahou PG(2010)Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM Bioinformatics 26 i237-245

[11] Selvaraj A(2008)Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer The Journal of clinical investigation 118 3065-3074

[12] Liu Y(2005)The coordinate regulation of the p53 and mTOR pathways in cells Proceedings of the National Academy of Sciences of the United States of America 102 8204-8209

[13] Kozma SC(2005)Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23 7721-7735

[14] Thomas G(2003)Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Molecular endocrinology 17 575-588

[15] Sonenberg N(2011)The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells Molecular endocrinology 25 516-528

[16] Gulhati P(2005)Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clinical cancer research : an official journal of the American Association for Cancer Research 11 5319-5328

[17] Bowen KA(2007)Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells The Journal of surgical research 138 37-44

[18] Liu J(2013)The UCSC Cancer Genomics Browser: update 2013 Nucleic acids research 41 D949-954

[19] Stevens PD(2011)The UCSC Cancer Genomics Browser: update 2011 Nucleic acids research 39 D951-959

[20] Rychahou PG(2010)Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM Bioinformatics 26 i237-245